Suhua Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Suhua Li has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Jun-Lin Guan
Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
8 shared publications - Kanakaraju Manupati
Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio
8 shared publications - Mingang Hao
Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio
8 shared publications - Sushma Maharjan
Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio
8 shared publications - Aihua Zheng
State Key Laboratory of Animal Biodiversity Conservation and Integrated Pest Management, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
1 shared publication Changyao Li
Affiliation College of Veterinary Medicine, China Agricultural University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
Supplementary Figure S6 shows effect of rapamycin on 4E-BP1 phosphorylation and migration of PI3KC2β KO cells.
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
Supplementary Figure S6 shows effect of rapamycin on 4E-BP1 phosphorylation and migration of PI3KC2β KO cells.
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
Supplementary Figure S2 shows effects of PI3KC2β overexpression on migration and invasion of mouse and human breast cancer cells.
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
Supplementary Figure S2 shows effects of PI3KC2β overexpression on migration and invasion of mouse and human breast cancer cells.
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
HER2 amplification or mutation accounts for 25% of patients with breast cancer that can advance to metastatic disease. Therefore, it is important to identify novel genes that mediate metastasis in HER2+ breast cancer. In this study, we describe a new metastatic suppressor gene, class II phosphatidylinositol 3-kinase β (Pi3kc2β), through in vivo CRISPR-Cas9 library screening of a custom-designed library targeting genes implicated in autophagy using murine HER2+ breast cancer (N418) cells. We further showed that PI3KC2β knockout N418 cells increased their migration and invasion in vitro and lung metastasis in both spontaneous and experimental metastasis assays in vivo. Analysis of databases and tissue samples from patients with breast cancer correlated lower expression of PI3KC2β with decreased metastasis, overall survival, and relapse-free survival. Further, PI3KC2β deletion induced the activation of mTORC1 signaling, independent of affecting its kinase activity. Mechanistically, we found that PI3KC2β forms a complex with intersectin 1 (ITSN1) and raptor that could be decreasing the stability of raptor, and deletion of either PI3KC2β or ITSN1 led to increased raptor levels and mTORC1 signaling. Lastly, rapamycin treatment reduced the migration and invasion of PI3KC2β knockout tumor cells in vitro and their lung metastasis in vivo, supporting an important role of the mTORC1 pathway. Together, our results identify PI3KC2β as a suppressor of HER2+ breast cancer metastasis by negatively regulating mTORC1 signaling by affecting its complex formation with ITSN1 and raptor.Implications:Our findings revealed PI3KC2β as a new metastasis suppressor for HER2+ breast cancer, which might serve as a potential diagnostic and therapeutic target for the disease.
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
HER2 amplification or mutation accounts for 25% of patients with breast cancer that can advance to metastatic disease. Therefore, it is important to identify novel genes that mediate metastasis in HER2+ breast cancer. In this study, we describe a new metastatic suppressor gene, class II phosphatidylinositol 3-kinase β (Pi3kc2β), through in vivo CRISPR-Cas9 library screening of a custom-designed library targeting genes implicated in autophagy using murine HER2+ breast cancer (N418) cells. We further showed that PI3KC2β knockout N418 cells increased their migration and invasion in vitro and lung metastasis in both spontaneous and experimental metastasis assays in vivo. Analysis of databases and tissue samples from patients with breast cancer correlated lower expression of PI3KC2β with decreased metastasis, overall survival, and relapse-free survival. Further, PI3KC2β deletion induced the activation of mTORC1 signaling, independent of affecting its kinase activity. Mechanistically, we found that PI3KC2β forms a complex with intersectin 1 (ITSN1) and raptor that could be decreasing the stability of raptor, and deletion of either PI3KC2β or ITSN1 led to increased raptor levels and mTORC1 signaling. Lastly, rapamycin treatment reduced the migration and invasion of PI3KC2β knockout tumor cells in vitro and their lung metastasis in vivo, supporting an important role of the mTORC1 pathway. Together, our results identify PI3KC2β as a suppressor of HER2+ breast cancer metastasis by negatively regulating mTORC1 signaling by affecting its complex formation with ITSN1 and raptor.Implications:Our findings revealed PI3KC2β as a new metastasis suppressor for HER2+ breast cancer, which might serve as a potential diagnostic and therapeutic target for the disease.
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
Supplementary Figure S5 shows RAPTOR translation level in PI3KC2β WT and KO tumor cells.
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
Supplementary Figure S5 shows RAPTOR translation level in PI3KC2β WT and KO tumor cells.
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
Supplementary Figure S3 shows AKT inhibitor triciribine reduces 4E-BP1 phosphorylation in PI3KC2β KO cells (panel A), and increased 4E-BP1 phosphorylation in PI3KC2β KO cells (Panel B).
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
Supplementary Figure S3 shows AKT inhibitor triciribine reduces 4E-BP1 phosphorylation in PI3KC2β KO cells (panel A), and increased 4E-BP1 phosphorylation in PI3KC2β KO cells (Panel B).
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
Supplementary Figure S1 shows Ki67+ cells in lung sections of recipient mice transplanted with PI3KC2β WT and KO tumor cells.
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
Supplementary Figure S1 shows Ki67+ cells in lung sections of recipient mice transplanted with PI3KC2β WT and KO tumor cells.
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
Supplementary Figure S4 shows PI(3,4)P2 and PI(4)P levels in PI3KC2β WT and KO tumor cells (Panels A and B) and lung metastasis nodules in recipient mice with tail vein injection of N418 cells transfected with vector control or PI3KC2β kinase-defective mutant (Panels C and D).
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
Supplementary Figure S4 shows PI(3,4)P2 and PI(4)P levels in PI3KC2β WT and KO tumor cells (Panels A and B) and lung metastasis nodules in recipient mice with tail vein injection of N418 cells transfected with vector control or PI3KC2β kinase-defective mutant (Panels C and D).
- 13 May 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 23 (9) , 765-778
Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
HER2 amplification or mutation accounts for 25% of patients with breast cancer that can advance to metastatic disease. Therefore, it is important to identify novel genes that mediate metastasis in HER2+ breast cancer. In this study, we describe a new metastatic suppressor gene, class II phosphatidylinositol 3-kinase β (Pi3kc2β), through in vivo CRISPR-Cas9 library screening of a custom-designed library targeting genes implicated in autophagy using murine HER2+ breast cancer (N418) cells. We further showed that PI3KC2β knockout N418 cells increased their migration and invasion in vitro and lung metastasis in both spontaneous and experimental metastasis assays in vivo. Analysis of databases and tissue samples from patients with breast cancer correlated lower expression of PI3KC2β with decreased metastasis, overall survival, and relapse-free survival. Further, PI3KC2β deletion induced the activation of mTORC1 signaling, independent of affecting its kinase activity. Mechanistically, we found that PI3KC2β forms a complex with intersectin 1 (ITSN1) and raptor that could be decreasing the stability of raptor, and deletion of either PI3KC2β or ITSN1 led to increased raptor levels and mTORC1 signaling. Lastly, rapamycin treatment reduced the migration and invasion of PI3KC2β knockout tumor cells in vitro and their lung metastasis in vivo, supporting an important role of the mTORC1 pathway. Together, our results identify PI3KC2β as a suppressor of HER2+ breast cancer metastasis by negatively regulating mTORC1 signaling by affecting its complex formation with ITSN1 and raptor. Implications: Our findings revealed PI3KC2β as a new metastasis suppressor for HER2+ breast cancer, which might serve as a potential diagnostic and therapeutic target for the disease.
- 13 May 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 23 (9) , 765-778
Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer
HER2 amplification or mutation accounts for 25% of patients with breast cancer that can advance to metastatic disease. Therefore, it is important to identify novel genes that mediate metastasis in HER2+ breast cancer. In this study, we describe a new metastatic suppressor gene, class II phosphatidylinositol 3-kinase β (Pi3kc2β), through in vivo CRISPR-Cas9 library screening of a custom-designed library targeting genes implicated in autophagy using murine HER2+ breast cancer (N418) cells. We further showed that PI3KC2β knockout N418 cells increased their migration and invasion in vitro and lung metastasis in both spontaneous and experimental metastasis assays in vivo. Analysis of databases and tissue samples from patients with breast cancer correlated lower expression of PI3KC2β with decreased metastasis, overall survival, and relapse-free survival. Further, PI3KC2β deletion induced the activation of mTORC1 signaling, independent of affecting its kinase activity. Mechanistically, we found that PI3KC2β forms a complex with intersectin 1 (ITSN1) and raptor that could be decreasing the stability of raptor, and deletion of either PI3KC2β or ITSN1 led to increased raptor levels and mTORC1 signaling. Lastly, rapamycin treatment reduced the migration and invasion of PI3KC2β knockout tumor cells in vitro and their lung metastasis in vivo, supporting an important role of the mTORC1 pathway. Together, our results identify PI3KC2β as a suppressor of HER2+ breast cancer metastasis by negatively regulating mTORC1 signaling by affecting its complex formation with ITSN1 and raptor. Implications: Our findings revealed PI3KC2β as a new metastasis suppressor for HER2+ breast cancer, which might serve as a potential diagnostic and therapeutic target for the disease.
- Open Access
- 8 March 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (3) , e1009393
ADAM17 is an essential attachment factor for classical swine fever virus
Classical swine fever virus (CSFV) is an important pathogen in the swine industry. Virion attachment is mediated by envelope proteins Erns and E2, and E2 is indispensable. Using a pull-down assay with soluble E2 as the bait, we demonstrated that ADAM17, a disintegrin and metalloproteinase 17, is essential for CSFV entry. Loss of ADAM17 in a permissive cell line eliminated E2 binding and viral entry, but compensation with pig ADAM17 cDNA completely rescued these phenotypes. Similarly, ADAM17 silencing in primary porcine fibroblasts significantly impaired virus infection. In addition, human and mouse ADAM17, which is highly homologous to pig ADAM17, also mediated CSFV entry. The metalloproteinase domain of ADAM17 bound directly to E2 protein in a zinc-dependent manner. A surface exposed region within this domain was mapped and shown to be critical for CSFV entry. These findings clearly demonstrate that ADAM17 serves as an essential attachment factor for CSFV.
- 8 March 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (3) , e1009393
Open AccessADAM17 is an essential attachment factor for classical swine fever virus
Classical swine fever virus (CSFV) is an important pathogen in the swine industry. Virion attachment is mediated by envelope proteins Erns and E2, and E2 is indispensable. Using a pull-down assay with soluble E2 as the bait, we demonstrated that ADAM17, a disintegrin and metalloproteinase 17, is essential for CSFV entry. Loss of ADAM17 in a permissive cell line eliminated E2 binding and viral entry, but compensation with pig ADAM17 cDNA completely rescued these phenotypes. Similarly, ADAM17 silencing in primary porcine fibroblasts significantly impaired virus infection. In addition, human and mouse ADAM17, which is highly homologous to pig ADAM17, also mediated CSFV entry. The metalloproteinase domain of ADAM17 bound directly to E2 protein in a zinc-dependent manner. A surface exposed region within this domain was mapped and shown to be critical for CSFV entry. These findings clearly demonstrate that ADAM17 serves as an essential attachment factor for CSFV.